Abstract :
Primary immune thrombocytopenia is an autoimmune condition in which the quantity of platelets in the blood is significantly decreased. It can affect both pediatrics and adults. Immune thrombocytopenia is linked to recurrent bruising and bleeding due to low platelet levels, which can be caused by a variety of reasons, including impaired thrombopoiesis and immunological responses that contribute to platelet destruction under pathological conditions. The disease has been considered one of the identified hematological diseases in Malaysia. A total of six primary immune thrombocytopenia articles among children and adults in Malaysia were identified in the academic database published between 2008 and 2020. The publication on primary immune thrombocytopenia in Malaysia was considered low, with a rate of 0.50 publications per year. Even though immune thrombocytopenia is recognizable in the country, the disease is not gaining much attention compared to other hematological and autoimmune disorders. The true incidence of primary immune thrombocytopenia in the country could not be determined, and thus remains unknown. Patient outcomes and disease clinical presentation are case-specific, pointing to immune thrombocytopenia rather than a collection of clinical conditions with similar symptoms. Loss of immunological tolerance to platelet antigens and primary hemostasis failure are two of the most common symptoms. Because of the heterogeneity of the patient population and their characteristics, clinicians have to choose an appropriate therapeutic regimen.
